Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Wave Life Sciences Ltd. - Ordinary Shares (NQ:WVE)

5.920 +0.080 (+1.37%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Wave Life Sciences Ltd. - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 Next >
Wave Life Sciences to Present at Chardan 8th Annual Genetic Medicines Conference
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Wave Life Sciences Prices Upsized $200 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
General Motors To $42? Here Are 10 Top Analyst Forecasts For Wednesday
Via Benzinga
Deep Dive Into WAVE Life Sciences Stock: Analyst Perspectives (4 Ratings)
Via Benzinga
What Analysts Are Saying About WAVE Life Sciences Stock
Via Benzinga
WAVE Life Sciences Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)
Via Benzinga
Stitch Fix Reports Weak Earnings, Joins KB Home And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
Wave Life Sciences Announces Proposed Public Offering of Ordinary Shares and Pre-Funded Warrants
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Crude Oil Gains Over 1%; BioVie Shares Plunge
Via Benzinga
Exposures Fossil Fuels
Nasdaq Surges 100 Points; Thor Industries Earnings Top Views
Via Benzinga
Wave Life Sciences Stock Surges On Promising Interim Data From Mid-Stage Study Of Muscular Disorder Drug
Wave Life Sciences reveals positive interim data from its Phase 2 FORWARD-53 study on WVE-N531 for Duchenne muscular dystrophy patients. Results show improved muscle health, dystrophin production, and... 
Via Benzinga
Wave Life Sciences, Nio, Li Auto, Tesla And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Wave Life Sciences Announces Positive Interim Data from FORWARD-53 Clinical Trial Evaluating WVE-N531 in Boys with Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Analysts Predict 85% Upside for Wave Life Sciences After Rate Cut
Wave Life Sciences has received recent Wall Street price targets forecasting big upside. The company has a potentially "industry-leading" treatment. 
Via MarketBeat
Topics Economy
Exposures Interest Rates
Gene Editing Korro Bio's Preclinical Data 'Best-In-Class', Analyst Initiates With Outperform Rating
William Blair initiates coverage on Korro Bio highlighting its innovative RNA editing platform, ADAR-based OPERA. The analyst rates the stock Outperform, noting its potential in treating alpha-1... 
Via Benzinga
Wave Life Sciences Receives FDA Rare Pediatric Disease Designation for WVE-N531 for the Treatment of Duchenne Muscular Dystrophy
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
WVE Stock Earnings: WAVE Life Sciences Misses EPS, Misses Revenue for Q2 2024
WVE stock results show that WAVE Life Sciences missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. 
Via InvestorPlace
Wave Life Sciences Reports Second Quarter 2024 Financial Results and Provides Business Update
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Wave Life Sciences Second Quarter 2024 Financial Results Scheduled for August 8, 2024
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Worthington Enterprises Posts Downbeat Results, Joins Taysha Gene Therapies, General Mills And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
What's Going On With Wave Life Sciences Stock On Tuesday?
Wave Life Sciences reports Phase 1b/2a SELECT-HD trial results for WVE-003 in Huntington's disease, demonstrates promise as a disease-modifying therapy. 
Via Benzinga
Wave Life Sciences Announces Positive Results from Phase 1b/2a SELECT-HD Trial with First Clinical Demonstration of Allele-Selective Mutant Huntingtin Lowering in Huntington’s Disease
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Wave Life Sciences Announces Upcoming Presentations Highlighting Novel siRNA Program in Obesity and Leadership in RNA Editing
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Wave Life Sciences to Present at 2024 Jefferies Global Healthcare Conference
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
WVE Stock Earnings: WAVE Life Sciences Misses EPS, Misses Revenue for Q1 2024
WVE stock results show that WAVE Life Sciences missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
Wave Life Sciences Reports First Quarter 2024 Financial Results and Provides Business Update
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Wave Life Sciences Announces Appointment of Dr. Erik Ingelsson as Chief Scientific Officer
Appointment builds on Wave’s recent progress advancing innovative genetic targets, such as INHBE, and continues to add significant experience to accelerate the rapid identification and translation of... 
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Wave Life Sciences to Present at 2024 RBC Capital Markets Global Healthcare Conference
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Wave Life Sciences First Quarter 2024 Financial Results Scheduled for May 9, 2024
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Wave Life Sciences Announces Approval of First Clinical Trial Application for RestorAATion-2 Trial of WVE-006 in Individuals with Alpha-1 Antitrypsin Deficiency (AATD)
Proof-of-mechanism data for WVE-006 in individuals with AATD remain on track for 2024 
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.